迈科康生物 迈科康生物

CN

We focus on the R&D and production of innovative vaccines and new adjuvants.

about

mAXVAX

We focus on the R&D and production of innovative vaccines and new adjuvants.

Maxvax Biotechnology was founded by Dr. Dexiang Chen in 2016 in China's south-western city of Chengdu. We are a global biopharmaceutical enterprise dedicated to the research, development, production and commercialization of innovative vaccines and new adjuvants.
More

Technology

& production

We provide customers with high-quality, safe
and innovative products.

Technology Platform

Maxvax has pioneered three technological platforms: recombinant protein, adjuvants, and mRNA, aimed at treating infectious diseases, cancer, and allergies.

Learn more

Technology
Platform

+

Pipeline Introduction

Utilizing our technology platforms, we have developed a diverse pipeline of prophylactic and therapeutic vaccines to combat global health burdens.

Learn more

Pipeline
Introduction

+

Production Capability

We have constructed over 200,000 sq ft of state-of-the-art R&D and manufacturing facilities to support our pipeline, enabling us to handle product development all the way to industrial scale manufacturing, all in-house.

Learn more...

Production
Capability

+

news

center

Maxvax Newsletters

  • 112025.01

    Maxvax’s Novel Adjuvant Team Publishes Article on World Renowned Journal

    Maxvax's innovative novel adjuvant team has successfully published a landmark research article in one of the world’s most prestigious scientific journals, Angewandte Chemie International Edition (Impact Factor 16.1).

    more >

  • 082025.01

    Financing Progress | Maxvax Completes Convertible Bond Financing of RMB 200M

    Chengdu Maxvax Biotechnology LLC (Maxvax) announced the completion of a 200-million-yuan convertible bond financing on the day following New Year’s Day, with investment from Shenzhen Capital Group’s (SCGC) National New Materials Fund for Manufacturing Transformation and Upgrading.

    more >

  • 142024.11

    Maxvax Launches Clinical Trials for RSV Vaccine

    On November 10, 2024, the kick-off meeting of the Phase I/II clinical trial of the recombinant respiratory syncytial virus (RSV) vaccine (CHO cell) independently developed by Maxvax was held in China’s Henan Province, and the enrollment of the first subjects was completed on the same day, marking the official start of the clinical trial of this vaccine candidate.

    more >
See more

contact

mAXVAX

We are here if you have any questions and needs.

  • Contact Us

  • Opportunities

  • Branches